Concanamycin A (purity≥90%)

Concanamycin A (purity≥90%) (Antibiotic X 4357B) is a macrolide antibiotic, a vacuolar type H⁺-ATPase (V-ATPase) inhibitor. Concanamycin A (purity≥90%) is also an inhibitor of lysosomal acidification, can be used to T cell-mediated inflammation research^[1]-[5]. IC50 & Target:Vacuolar type H⁺-ATPase^[1] In Vitro:Concanamycin A (purity≥90%) can come from S. diastatochromogenes, as a microbial metabolite with immunomodulatory activity^[1].
Concanamycin A (purity≥90%) (100 nM; 0-20 h) results DNA fragmentation in CD4⁺ and selectively induces CD8⁺ T cells rapid cell death between normal and the immunized mice source, while CD8⁺ population in mice immunized is more sensitive^[2].
Concanamycin A (purity≥90%) (3-50 nM; 16 h) inhibits LPS-induced NO production in elicited peritoneal macrophages, but (25 nM; 7 h) doesn’t inhibit LPS-induced TNF-α production^[3].
Concanamycin A (purity≥90%) (0.01 nM-1 nM) inhibits the acidification of rat liver lysosomes (IC₅₀ =0.061 nM), and inhibits oleate incorporation into cholesteryl ester (IC₅₀ =14 nM)^[4].
In Vivo:Concanamycin A (purity≥90%) (15 mg/kg; i.v.; 0, 10 or 24 h prior to sacrifice) induces T cell-mediated hepatitis in mice^[5].